Edwards Lifesciences (EW) Gross Margin (2009 - 2026)

Edwards Lifesciences' Gross Margin history runs 18 years deep, the most recent figure standing at 78.01% for Q1 2026.

• In Q1 2026, Gross Margin fell 65.0% year-over-year to 78.01%; the TTM figure through Mar 2026 stood at 77.87% (down 163.0% YoY), while the FY2025 annual figure was 78.01%, down 144.0% from the prior year.
• Gross Margin was 78.01% for Q1 2026 at Edwards Lifesciences, roughly flat from 78.15% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 122.98% in Q4 2022 to a low of 77.52% in Q2 2025.
• Historically, Gross Margin has averaged 81.86% across 5 years, with a median of 79.85% in 2023.
• The sharpest annual moves came in 2022 and 2023: Gross Margin surged 4626 bps in 2022, then tumbled 4280 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 122.98% in 2022, then slumped by 35 bps to 80.18% in 2023, then fell by 2 bps to 78.91% in 2024, then retreated by 1 bps to 78.15% in 2025, then dropped by 0 bps to 78.01% in 2026.
• The last three Gross Margin figures came in at 78.01% (Q1 2026), 78.15% (Q4 2025), and 77.77% (Q3 2025), per Business Quant data.